Summary statements
| Summary statements . |
|---|
| 1. We feel comfortable using standard treatment doses of DOACs in patients with VTE or AF and a body weight >120 kg and/or BMI >40 kg/m2 as long as there is shared decision-making after an informed discussion of available evidence; More prospective studies are needed in morbidly obese patients, particularly in the VTE population |
| 2. We avoid the use of DOACs in patients after bariatric surgery and await further clinical trials |
| 3. We use the standard VTE prevention doses of DOACs in morbidly obese patients who require thromboprophylaxis after surgery |
| 4. We do not routinely monitor DOAC levels in the morbidly obese population outside of clinical trial setting |
| Summary statements . |
|---|
| 1. We feel comfortable using standard treatment doses of DOACs in patients with VTE or AF and a body weight >120 kg and/or BMI >40 kg/m2 as long as there is shared decision-making after an informed discussion of available evidence; More prospective studies are needed in morbidly obese patients, particularly in the VTE population |
| 2. We avoid the use of DOACs in patients after bariatric surgery and await further clinical trials |
| 3. We use the standard VTE prevention doses of DOACs in morbidly obese patients who require thromboprophylaxis after surgery |
| 4. We do not routinely monitor DOAC levels in the morbidly obese population outside of clinical trial setting |